- SciSparc Ltd. (SPRC, Financial) regains compliance with Nasdaq's minimum bid price requirement.
- The company's shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days.
- Nasdaq has closed the previous bid price deficiency matter, ensuring continued listing.
SciSparc Ltd. (SPRC), a clinical-stage pharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement, according to an official notification received on July 18, 2025. The company's stock maintained a closing bid price of $1.00 or higher for 10 consecutive business days, meeting the criteria set by Nasdaq Listing Rule 5550(a)(2).
This compliance achievement marks an important milestone for SciSparc, as it resolves the previous deficiency in bid price and secures the company’s continued listing on the Nasdaq exchange. This development is likely to provide a level of stability for investors, removing the risk of delisting and reinforcing confidence in SciSparc's market position.
SciSparc Ltd., with a focus on developing therapies for central nervous system disorders and rare diseases, is currently engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus. The company also holds a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.com.
